FDA signs off on Sobi's Kineret for COVID patients with pneumonia who are on oxygen

The FDA has added another drug to its evolving roster of COVID-19 medicines. The agency authorized (PDF) Sobi's Kineret for patients hospitalized with the virus and who are on pneumonia, require supplemental oxygen, are at risk for progressing to severe respiratory failure and are likely to have an elevated level of a specific protein.